End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 MYR | +1.35% | +7.91% | +6.38% |
03-12 | UMediC Group's Profit Slips in Fiscal Q2; Shares Rise 3% | MT |
03-11 | UMediC Group Berhad Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an enterprise value anticipated at 4.53 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.38% | 59.09M | - | ||
-5.43% | 182B | C+ | ||
+4.30% | 114B | C | ||
-3.09% | 68.38B | A | ||
+5.86% | 52.46B | B- | ||
+8.15% | 44.25B | B- | ||
+7.52% | 43.55B | B+ | ||
+25.54% | 32.69B | B | ||
+17.85% | 26.73B | A- | ||
+1.00% | 25.79B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UMC Stock
- Ratings UMediC Group